Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations

פריטים דומים

• Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors
  מאת: Chih-Yen Tu, et al.
  יצא לאור: (2024-01-01)
• The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan
  מאת: Wen‐Chien Cheng, et al.
  יצא לאור: (2022-05-01)
• Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma
  מאת: Chen, Hung-Jen, et al.
  יצא לאור: (2020)
• Endobronchial Ultrasound Changed the World of Lung Cancer Patients: A 11-Year Institutional Experience
  מאת: Chen, Chia-Hung, et al.
  יצא לאור: (2015)
• Interventional pulmonology for patients with central airway obstruction: An 8-year institutional experience
  מאת: Chen, Chia-Hung, et al.
  יצא לאור: (2017)